Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 05:37 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements
NCT04093362 · Taiho Oncology, Inc. · PHASE3 · terminated · last registry update 2025-02-07 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Due to Poor Recruitment” | – | Registry record, Taiho Oncology, Inc. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against FGFR3 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-02-06Also stopped (terminated): M.D. Anderson Cancer Center, Erdafitinib (NCT04754425)
- 2026-01-13Phase 3 first posted: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company, BMS-986353 + Fludarabine (NCT07335562)
- 2026-01-13Also stopped (terminated): Novartis Pharmaceuticals, LTP001 + Placebo (NCT05497284)
- 2025-12-31Results posted on the registry: Taiho Oncology, Inc., Futibatinib + Pembrolizumab (NCT04601857)
- 2025-12-31Also stopped (terminated): Taiho Oncology, Inc., Futibatinib + Pembrolizumab (NCT04601857)
- 2025-12-30Results posted on the registry: Incyte Corporation, Pemigatinib (NCT05267106)
- 2025-12-30Also stopped (terminated): Incyte Corporation, Pemigatinib (NCT05267106)
- 2025-12-23Phase 3 first posted: Argyrios Tzouvelekis, Intravenous immunoglobulin (IVIG) + Usual treatment (NCT07299695)
- 2025-12-16Results posted on the registry: Eisai Co., Ltd., E7090 (NCT02275910)
- 2025-12-02Results posted on the registry: Boehringer Ingelheim, BI 1015550 + Nintedanib (NCT06070610)
- 2025-11-18Results posted on the registry: Incyte Corporation, Pemigatinib (NCT03011372)
- 2025-11-13Results posted on the registry: Taiho Oncology, Inc., Futibatinib + Futibatinib plus Fulvestrant (NCT04024436)
- 2025-11-13Also stopped (terminated): Taiho Oncology, Inc., Futibatinib + Futibatinib plus Fulvestrant (NCT04024436)
- 2025-11-04Also stopped (terminated): Incyte Corporation, Pemigatinib (NCT03822117)
- 2025-11-04Also stopped (terminated): Incyte Corporation, Pemigatinib + Pembrolizumab (NCT04003610)
- 2025-10-29Results posted on the registry: Mayo Clinic, Futibatinib + Pembrolizumab (NCT04828486)
- 2025-10-24Results posted on the registry: Nader Sanai, Infigratinib (NCT04424966)
- 2025-10-24Also stopped (terminated): Nader Sanai, Infigratinib (NCT04424966)
- 2025-10-21Also stopped (withdrawn): National Cancer Institute (NCI), Atezolizumab + Erdafitinib (NCT05564416)
- 2025-10-08Results posted on the registry: Taiho Oncology, Inc., Futibatinib (NCT04189445)
- 2025-10-08Also stopped (terminated): Taiho Oncology, Inc., Futibatinib (NCT04189445)
- 2025-09-19Also stopped (terminated): European Organisation for Research and Treatment of Cancer - EORTC, Nintedanib + Placebo (NCT02863055)
- 2025-09-18Results posted on the registry: Novartis Pharmaceuticals, LTP001 + Placebo (NCT05497284)
- 2025-09-17Results posted on the registry: M.D. Anderson Cancer Center, Futibatinib + Pembrolizumab (NCT05036681)
- 2025-09-16Phase 3 first posted: AB Science, Masitinib 4.5 mg/kg/day + Placebo (NCT07174492)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision